Articles

Verteporfin Hair Transplant Surgery Trial With Dr. Bloxham

July 28, 2023 /

Seeking Scarless Hair Transplants With Donor Regeneration On July 11th, 2023, Dr. Blake Bloxham completed a verteporfin trial in his New York office. The trial focused on testing verteporfin’s effect on minimizing scarring or potentially producing scarless healing during a hair transplant procedure. Dr. Bloxham treated three different patients undergoing FUT (Follicular Unit Transplantation) hair…

Read More

Allogeneic “Off The Shelf” PRP For Hair Loss 2023: Carmell Therapeutics

July 25, 2023 /

Carmell Therapeutics Merger Finalization Update (09/12/2023) As of September 12th, 2023, Carmell Therapeutics has finalized a merger with a regenerative medicine company called Axolotl Biologix. The company names it a “significant development for the future of regenerative medicine”. Axolotl Biologix is a company that conducts research in regenerative medicines to design and develop human amniotic…

Read More

Mallia Therapeutics Secures Funding For Hair Growth Drug CD83

July 11, 2023 /

The German biotech startup Mallia Therapeutics (formerly MalliaBiotech) has secured seed funding to further its hair loss drug soluble CD83. CD83 Hair Growth Through Immune Modulation On July 11, 2023, Mallia Therapeutics issued a press release announcing a successful seed financing round and the presentation of data at a European Hair Research Society (EHRS) meeting.…

Read More

AI Discovers New Hair Loss Drug: LCH34

July 3, 2023 /

Life Code shares poster from the 25th World Congress of Dermatology Singapore 2023 with Follicle Thought. Artificial Intelligence Small Molecule Enhanced Hair Growth Follicle Thought is pleased to share an exclusive look at Life Code’s poster from the current World Congress of Dermatology event. Just over a year ago, I shared an introduction to Life…

Read More

Amplifica Begins Trial For AMP-303

June 28, 2023 /

On June 28, 2023, Amplifica Holdings Group announced the initiation of a clinical trial for one of its lead candidate molecules from the study of hairy moles. Amplifica’s AMP-303 has officially entered a clinical trial. According to a news release on the company’s website and PR Newswire, the first patient was dosed in a multicenter,…

Read More

StimuSIL’s SAGA-001: A New Paradigm in Laser Therapy for Hair Loss

June 19, 2023 /

Follicle Thought is pleased to announce a new company developing a treatment for androgenetic alopecia with an innovative technology. Unlike most other biotechs tackling the challenging field of hair regeneration, StimuSIL is a biomedical device company. Their team has created a completely new way to deliver photobiomodulation and incorporated it into a proprietary, patented hair…

Read More

AnHorn Medicines: New Androgen Receptor Degrader For Hair 2023

June 6, 2023 /

A company working in protein degradation has entered the field of hair loss therapeutics in Spring 2023 with a new anti-hair loss drug. AH-001 AnHorn Medicines As I’ve stated before, we are in a new era for hair loss medication. Whereas in years past we would see a new therapy or company emerge once per…

Read More

InovAUGMET Research Unveils New Website

May 26, 2023 /

An Indian drug-discovery startup with a focus on dermatology has unveiled its new website. Inovaugmet Research, which was mentioned in a recent article on Follicle Thought, is aiming to bring new therapies to unmet dermatological needs. Inovaugmet utilizes a dermatology-specific drug discovery platform called iNeu-3D screen to find new molecules. From the company’s website, iNeu-3D…

Read More

Follicum Comes Back To Share New FOL005 Presentation May 2023

May 16, 2023 /

After a more thorough evaluation of FOL-005’s data from a phase 2 clinical trial, new management at Follicum believes that its drug candidate has a place in the treatment landscape for androgenic alopecia and they want to explain why. FOL-005 Phase 2 Results Revisited In February 2022, Follicum AB was acquired by Coegin Pharma, a…

Read More

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.